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English summary 
 
Background: Iodine deficiency (ID) has been and remains a global health issue of 
considerable importance. ID may lead to impaired neurological development among 
children and the development of toxic and non-toxic nodular goitre among adults. 
Salt iodization is considered a safe and effective way to alleviate ID within a 
population, yet adverse effects such as increased incidence of hypothyroidism and a 
transient increase in thyrotoxicosis incidence have been linked to iodine fortification 
(IF) programs. Voluntary salt iodization in Denmark was initiated in July 1998 (8 
ppm) and replaced with mandatory salt iodization (13 ppm) in July 2000.  
Purpose: The purpose of this dissertation has been to investigate the impact of salt 
iodization on the incidence rates of overt thyroid dysfunction and its nosological 
subtypes in Denmark. 
Methods: All new cases of overt thyroid dysfunction were monitored in two areas 
of Denmark with different pre-existing levels of ID before and long after the 
introduction of salt iodization. These open cohorts encompassed around 10% of the 
Danish population at the initiation of the study. The first cohort was located in 
Northern Jutland (moderate ID prior to IF)) while the other cohort was located in the 
Danish capital Copenhagen (mild ID prior to IF). The identification of potential new 
cases of overt thyroid dysfunction was based on applying diagnostic algorithms to 
all thyroid function tests sampled within the cohort areas and subsequently 
contacting the current general practitioner of each case for verification. The 
monitoring program was initiated in the year 1997 and is still ongoing in Northern 
Jutland while the monitoring program in Copenhagen was concluded in the year 
2008. Individual manual scrutiny of the medical history of all cases discovered in 
the cohort area with previous moderate ID during the years 1997-00 and 2014-16 
was performed to determine the severity, duration, need for treatment and 
nosological subtype of each case of overt thyroid dysfunction.     
Results: A highly significant 50% decrease in the incidence rate of overt 
thyrotoxicosis was observed in the cohort with previous moderate ID between 1997-
00 and 2014-16. This was primarily the product of a substantial reduction in the 
incidence rate of multinodular toxic goitre (÷82%) and solitary toxic adenoma 
(÷74%). A smaller yet significant reduction in the incidence rate of Graves’ disease 
(÷33%) was also observed. Our monitoring program for hypothyroidism incidence 
found significant increases in both cohort areas following IF (+30% in the mild ID 
cohort in 2004-05 and +50% in the moderate ID cohort in 2014-16). However, 
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manual scrutiny of the medical history of all overtly hypothyroid cases between 
1997-00 and 2014-16 revealed that no increase in the incidence rate of 
hypothyroidism had occurred for the population as a whole when cases with 
spontaneous normalization of thyroid function, and no medical history suggesting a 
condition known to cause transitory thyroid dysfunction, were excluded from the 
analysis. An altered age distribution of new hypothyroid cases was however 
discovered in 2014-16 with more cases among the young and fewer cases among the 
elderly.    
Conclusions: Mandatory salt iodization successfully reduced the incidence rate of 
overt thyrotoxicosis in an area of Denmark with moderate ID prior to IF without 
causing an increased incidence rate of sustained overt hypothyroidism requiring 
treatment. 
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Danish summary/Dansk résumé 
 
Baggrund: Jodmangel har historisk været et betydeligt globalt sundhedsproblem. 
Jodmangel kan føre til hæmmet neurologisk udvikling blandt børn samt udviklingen 
af toksisk og non-toksisk multinodøs struma blandt voksne. Jodberigelse af salt bør 
betragtes som et relativt effektivt og sikkert tiltag for at mindske forekomsten af 
jodmangel blandt befolkningen, dog kan visse utilsigtede virkninger, såsom øget 
incidens af overt hypothyroidisme og en midlertidig stigning i incidensen af overt 
thyrotoksikose, følge implementeringen af jodberigelses programmer. Frivillig 
jodberigelse af salt blev introduceret i Denmark i juli 1998 (8 µg jod per gram salt) 
og efterfølgende erstattet med obligat jodberigelse af salt i juli 2000 (13 µg/g). 
Formål: Formålet med denne afhandling har været at undersøge effekten af den 
danske jodberigelse af salt på incidensraterne af overt thyrotoksikose, hypothyreose 
og deres forskellige undertyper.  
Metoder: Alle nye tilfælde af overt thyroidea-dysfunktion blev registreret i 2 
områder af Danmark med forskelligt forudgående niveau af jodmangel før og længe 
efter introduktionen af jodberiget salt. Disse to åbne kohorter omfattede omkring 10 
% af den danske befolkning da undersøgelsen startede. Den første kohorte lå 
placeret I Nordjylland (moderat jodmangel før jodberigelsen) og den anden kohorte 
var placeret i København (mild jodmangel før jodberigelsen). Identifikationen af 
potentielle nye tilfælde af overt thyroidea-dysfunktion beroede på anvendelsen af to 
diagnostiske algoritmer på alle thyroidea funktions prøver taget inden for 
kohorteområderne med efterfølgende verifikation af alle potentielle nye tilfælde hos 
patienternes almen praktiserende læger. Monitoreringsprogrammet blev påbegyndt i 
året 1997 og er stadig aktivt i Nordjylland, mens monitoreringsprogrammet blev 
afsluttet i København i år 2008. Manuel gennemgang af alt tilgængeligt 
journalmateriale blev udført for alle potentielle nye tilfælde af overt thyroidea 
dysfunktion i den nordjyske kohorte i perioderne 1997-00 og 2014-16 for at 
fastlægge sværhedsgrad, varighed, behandlingsbehov og undertype af thyroidea 
dysfunktion hos disse patienter.     
Resultater: Et højsignifikant fald i incidens-raten af overt thyrotoksikose på 50% 
blev observeret i kohorten med forudgående moderat jodmangel mellem 1997-00 og 
2014-16. Dette var primært forårsaget af substantielle reduktioner i incidens-raterne 
af multinodøs toksisk struma (÷82%) og solitært toksisk adenom (÷74%). En mindre 
reduktion i incidens-raten af Graves’ sygdom blev også fundet at været signifikant 
(÷33%). Vores monitoreringsprogram for hypothyreose fandt signifikante stigninger 
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i begge kohorteområder efter introduktionen af jodberiget salt (+30% i kohorten 
med forudgående mild jodmangel i årene 2004-05 og +50% i kohorten med 
forudgående moderat jodmangel i årene 2014-16). Her var der tale om enkelte 
blodprøvesæt, og udførlig verifikation var ikke påkrævet for at blive identificeret 
som case. Manuel gennemgang af journalmateriale for alle de overt hypothyroide 
tilfælde fundet i perioderne 1997-00 og 2014-16 afslørede dog at incidens-raten af 
overt hypothyreose ikke havde ændret sig efter jodberigelsen, hvis man 
ekskluderede tilfælde med spontan normalisering af thyroidea funktion, som ikke 
havde indikatorer for tilstande der normalt forårsager midlertidig thyroidea 
dysfunktion. En ændret aldersfordeling for incidens-raterne af overt hypothyreose 
var dog tydelig med flere unge og færre ældre tilfælde.    
Konklusioner: Obligat jodberigelse af salt fik succesfuldt reduceret incidens-raten 
af overt thyrotoksiskose i et område med forudgående moderat jodmangel uden at 
forårsage en stigning i incidens-raten af vedvarende og behandlingskrævende overt 
hypothyreose. 
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Chapter 1: Introduction 
 
1.1 Background 
 
1.1.1 Iodine deficiency 
 
Iodine deficiency (ID) is one of the most common micronutrient deficiencies in the 
world with more than two billion people still affected
1
. Insufficient iodine intake is 
the primary cause of iodine deficiency and remains extremely prevalent in certain 
geographical areas
1
. ID within a population is most commonly measured using spot 
urine concentrations of iodine
1
. Urinary iodine concentration (UIC) is a suitable 
estimate for iodine intake as 90% of ingested iodine is excreted in urine
2
. Spot urine 
concentrations of iodine are however largely dependent on an individual’s fluid 
intake and current level of hydration
3,4
, which is why the median UIC value for the 
entire sample population is often used when estimating iodine intake within an area. 
Alternatively, 24-hour urine collection or correction using creatinine concentration 
in a spot urine sample may be used to estimate iodine excretion more precisely at the 
level of the individual
5
. The World Health Organization recommends the median 
UIC among men, school age children and women who are not pregnant or lactating 
to be between 100 and 199 µg/l
1
. Median UIC between 50 and 99 µg/l is categorized 
at mild ID, between 20 and 49 µg/l as moderate ID and below 20 µg/l as severe ID
1
. 
Severe ID may lead to endemic cretinism resulting in substantially impaired 
neurological development in children
6
, this is however currently a relatively rare 
phenomenon
1
. Mild and moderate ID during pregnancy may also lead to impaired 
cognitive development among children albeit to a lesser degree
7
. Mild and moderate 
ID within a population can furthermore lead to the development of thyroid nodules 
and multinodular goiter, some percentage of which will be autonomously 
functioning and lead to thyrotoxicosis
8–11
. Endemic goiter, toxic and non-toxic 
multinodular goiter, endemic cretinism and impaired neurological development 
among other conditions can collectively be termed iodine deficiency disorders 
(IDDs). Around 31% of the global population remain affected by some degree of ID 
in spite of substantial efforts to eradicate IDDs
1
. 
 
 
13 
 
 
1.1.2 Iodine fortification 
 
Universal salt iodization (USI) is often recognized as one of the most cost-effective, 
safe and sustainable methods to eradicate ID
1,12
. Globally, it is estimated that around 
70 percent of households have access to iodized salt
1
. Though USI is effective in 
combatting IDDs, a sudden increase in iodine intake may also have some negative 
consequences with regard to thyroid function. A significant albeit temporary 
increase in the occurrence of thyrotoxicosis should be expected when initiating salt 
iodization among an iodine deficient population
13–15
. Some evidence suggests that 
this may both result from increased substrate availability for pre-existing 
autonomously functioning nodules as well as a temporary increase in the incidence 
rate of Graves’ disease (GD) due to increased thyroid autoimmunity
16,17
. In addition 
to a transient increase in the occurrence of thyrotoxicosis, an elevated frequency of 
hypothyroidism has been linked to increased iodine intake
18–22
. This may at least 
partly be the product of increased thyroid autoimmunity as indicated by the 
increased prevalence of thyroid auto-antibodies observed after initiation of salt 
iodization
23,24
. Both the transient increase in thyrotoxicosis incidence and the 
increased occurrence of hypothyroidism following salt iodization seems to primarily 
affect the younger age groups
15,19,22
. Thus, a cautious approach to iodine fortification 
should be advised with particular focus on the young. 
 
1.1.3 DanThyr 
 
During the 1990s, significant focus was granted to the investigation and eradication 
of IDDs among the Danish population
25
. Distinct geographical differences in the 
severity of ID within Denmark were present, with moderate ID predominant in the 
Western parts of the country and mild ID in the Eastern parts
26
. These differences in 
iodine intake among the population were primarily the product of variation in the 
iodine content of tap water
27
. A tendency for increased serum thyroid stimulating 
hormone (TSH) in late pregnancy among Danish women were indicative of 
insufficient thyroid hormone production during fetal development
28–30
. Furthermore, 
toxic and non-toxic multinodular goiter was quite frequent, particularly in the 
Western parts of Denmark among the elderly
26,31,32
. Iodine fortification of salt was to 
be introduced in order to combat IDDs among the population while the DanThyr 
project were launched to monitor the effects of salt iodization and if necessary to 
adjust it
25
. Voluntary iodization of table salt and salt used for the commercial 
production of bread at a level of 8 µg/g were introduced in July 1998
33
. The IF 
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program was aiming for a 50 µg increase in average daily iodine intake but this 
voluntary program only achieved a 5-10 µg increase
25,34
. Thus, voluntary salt 
iodization was replaced with mandatory iodization at a level of 13 µg/g in July 2000. 
Manufactures were however allowed to sell their storages of non-iodized salt 
produced prior to July 2000 for the remainder of the year, thus mandatory salt 
iodization was not fully in effect before the end of the year 2000. The DanThyr 
project was designed to be multifaceted and monitored the impact of salt iodization 
on several different levels:  
I. Two open cohorts with different levels of ID prior to initiation of IF (mild 
vs. moderate ID) were utilized for continuous registration of all new cases 
of overt thyroid dysfunction before and after introduction of iodized salt 
(figure 1). The cohorts encompassed around 10% of the Danish population 
at the initiation of the study in 1997
35
. Preliminary results from the cohort 
studies have been published previously
15,19
. Thorough individual scrutiny 
of the medical records of all cases with overt thyroid dysfunction 
discovered within the cohort areas between 1997 and 2000 was undertaken 
to compliment the monitoring program with data on: normalization of 
thyroid function, initiation of treatment and the specific nosological 
subtype of each case
10,36
. No such procedure had been performed for cases 
discovered after the introduction of mandatory salt iodization. 
II. Two cross-sectional studies and one follow-up study were performed in 
two areas of Denmark with different pre-existing levels of ID (mild vs. 
moderate) before and after initiation of iodine fortification
37–39
. These 
cross-sectional studies were conducted in: 1997-98 (C1a, n=4649), 2004-05 
(C2, n=3570), 2008-10 (C1b, n=2465; follow-up to C1a). The cross-
sectional studies were conducted within the aforementioned cohort areas 
(figure 1). The prevalence of subclinical and overt thyroid dysfunction 
among representative samples of the general population remains to be 
investigated past the year 2010. Median UIC values for subjects residing in 
the areas marked in figure 1 also remain to be investigated past this point.  
III. Various treatments for thyroid disease (radio-iodine therapy, thyroid 
surgery, anti-thyroid medication and levothyroxine therapy) have been 
continuously monitored on a national level since before salt iodization was 
introduced and is still ongoing
21,40–42
.  
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Figure 1: The two cohort areas utilized in the DanThyr studies. The Western cohort located 
in Northern Jutland encompassed a total of 309,434 subjects by January 1st, 1997, while the 
Eastern cohort located in the Danish capital Copenhagen contained 224,535 subjects. The 
population of the Western cohort had a median urinary iodine concentration (UIC) of 45 µg/l 
(moderate iodine deficiency) in 1997-98 among subjects not using iodine containing 
supplements, while the population of the Eastern cohort had a median UIC of 61 µg/l (mild 
iodine deficiency) during the same period.   
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1.2 Aims of this PhD thesis 
 
This PhD thesis aims to expand our existing knowledge about the impact of the 
Danish iodine fortification program on the changes in incidence rate of overt thyroid 
dysfunction by adding more than a decade to the previously published results from 
the DanThyr cohort studies
15,19
. Furthermore, the thesis aims to reveal how the 
occurrence of specific nosological subtypes of thyrotoxicosis and hypothyroidism 
has changed after the introduction of mandatory salt iodization in Denmark. The 
importance of follow-up investigation of cases with overt thyroid dysfunction will 
be evident when incidence rates from the monitoring program are compared to those 
obtained by our follow-up study. Widely different incidence rates may be discovered 
when normalization of thyroid function in relation to initiation of treatment are 
included in the verification process.  
The diagnostic and therapeutic blood sampling activity before and after mandatory 
salt iodization will also be subject to investigation. As will the TFT levels of overtly 
hypothyroid patients at the time of diagnosis.   
17 
 
 
Chapter 2: Methods 
 
2.1 Study I & II 
 
2.1.1 Purpose 
 
The purpose of the first and second study, included in the present dissertation, was 
to monitor the development in the incidence rate of diagnosed overt biochemical 
thyroid dysfunction in two areas of Denmark with different preexisting levels of 
iodine deficiency before and long after the initiation of salt iodization. The first 
study deals with overt biochemical thyrotoxicosis, while the second study 
investigates overt biochemical hypothyroidism.    
 
2.1.2 Study Setting 
 
Two open cohorts were used for monitoring the diagnostic incidence rate of overt 
thyrotoxicosis and hypothyroidism before and after implementation of salt 
iodization (figure 1). The first (Western) cohort was located in Northern Jutland and 
included Aalborg city with some surrounding municipalities (n=309,434 by January 
1
st
, 1997). The second (Eastern) cohort was located in the Danish capital 
Copenhagen (n=224,535 by January 1
st
, 1997). Based on data from the DanThyr 
cross-sectional studies, the median urinary iodine concentration (UIC) within the 
Western cohort was determined to be 45 µg/l (moderate ID) among subjects not 
using iodine-containing supplements before introduction of any salt iodization 
(1997-98), while the median UIC within the Eastern cohort during the same period 
was 61 µg/l (mild ID)
37
. A second cross-sectional study was conducted in 2004-05 
and determined that salt iodization successfully increased the median UIC 
significantly within both cohort areas (86 vs. 99 µg/l for the Western and Eastern 
cohort respectively)
38
. A follow-up to the first cross-sectional study was conducted 
in 2008-10 and found the median UICs for the Western and Eastern cohorts slightly 
decreased (73 and 76 µg/l)
39
.  
The first study (monitoring the incidence rate of overt thyrotoxicosis) covers a study 
period of 21 years (1997-2017), while the second study (monitoring the incidence 
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rate of overt hypothyroidism) covers a 20 year study period (1997-2016). The period 
before implementation of voluntary IF (1997-June 1998) was used as the baseline 
period in both studies. Due to a national structural reform, the boundaries of the 
Danish municipalities were restructured in January 2007, resulting in a small 
decrease in the size of the Western cohort (n=261,569 by January 1
st
, 2007), while 
the Eastern Cohort was left unaffected. Detailed information on the composition of 
the cohorts were provided yearly by Statistics Denmark
43
.  
 
2.1.3 Data Collection 
 
All TFTs performed within the cohort areas were collected and evaluated in a 
specially designed register database. Four laboratories handled the analysis of all 
TFTs sampled within the cohort areas; these were the laboratories at Aalborg 
University Hospital, Frederiksberg Hospital, Bispebjerg Hospital and the General 
Practitioners Laboratory in Copenhagen.  
In Denmark, all general practitioners (GPs), hospital departments and private 
practice specialists have unique referral identification numbers for laboratory 
services. All Danish citizens possess unique identification numbers in the 
Centralized Person Register (CPR), which is used for all interactions with the 
healthcare sector. The unique referral identification numbers and the CPR numbers 
allowed for the inclusion of only TFTs sampled from patients who resided inside the 
cohort areas. Less than one percent of subjects living within the cohort areas were 
consulting GPs outside the cohort areas
35
.  
All potential new cases of overt biochemical thyroid dysfunction were identified by 
subjecting all TFTs collected from patients residing within the cohort areas to the 
diagnostic algorithms specified below: 
Overt biochemical thyrotoxicosis: serum TSH < 0.2 mU/l combined with elevated 
serum total T3 and/or elevated serum total T4. 
Overt biochemical hypothyroidism: serum TSH > 5.0 mU/l combined with 
decreased serum total T4.  
Details on the reference ranges of the total T3 and total T4 assays used by each 
laboratory have been described previously
35
. To evaluate the diagnostic performance 
of the four laboratories, a serum reference panel was collected from 100 healthy 
subjects (50 men and 50 women) with ages between 20 and 45 years. This reference 
panel was stored in micotubes at ÷80°C to be used for assay comparison between the 
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four laboratories. These comparisons were made each time a new assay was 
introduced by one of the four laboratories.  
When patients were identified as potential new cases of overt biochemical thyroid 
dysfunction by the above-mentioned diagnostic algorithms, the present GP of each 
patient was contacted for confirmation of the patient’s status as a new case of overt 
thyroid dysfunction. If the patient had previously been diagnosed with overt thyroid 
dysfunction, the patient would be excluded from further analysis. In cases where the 
hospital records of the patients clearly indicated previous overt thyroid dysfunction 
contact to the GP was deemed unnecessary. Manual confirmation of each potentially 
new patient’s area of residence was conducted.  
 
Figure 2: The different levels of data extraction from the DanThyr cohort studies. The 
database collects all thyroid function tests (TFTs) from within the cohort area (general 
practitioners (GPs), hospital departments and specialists with private practice). Diagnostic 
algorithms are then applied to select potential new cases of overt thyroid dysfunction. The 
GPs of each potential new case is then contacted for preliminary verification. The monitoring 
program uses data from this preliminary verification to assess incidence rates (Study I & II). 
Finally the medical records of cases with preliminary verification may be searched within 
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limited time periods to gain final verification including follow-up and subtype classification 
(Study III).   
 
2.1.4 Statistics 
 
Changes in the sex and age composition of the cohort were adjusted using the 
method of direct standardization
44
 and thus the standardized incidence rates (SIRs) 
were calculated according to: 
1) SIR =
∑ (age and gender specific rates  × standard weights)
  ∑ (standard weights) 
 
 
The Danish population at January 1
st
, 2005 was used as the standard population. The 
SIR was noted in cases per 100,000 per year. Significance to baseline SIR was 
calculated using the 95% confidence intervals (95% CI) of the standardized 
incidence rate ratio (SIRR)
44
 in accordance with: 
2) Upper and lower 95% CI of SIRR =
SIR
Baseline SIR
1±(1.96/
SIR−Baseline SIR
√SE (SIR)2+SE (Baseline SIR)2 
Results were considered significant if the 95% CI for the SIRR did not include 1. 
For the statistical analysis IBM SPSS Statistics for Windows, Version 25.0. 
Armonk, NY: IBM Corp was used.     
      
 
2.2 Study III 
 
2.2.1 Purpose 
 
The purpose of the third study in the present dissertation was to investigate changes 
in the incidence rates of specific nosological subtypes of overt thyrotoxicosis and 
hypothyroidism in an area with previous moderate ID after introduction of cautious 
mandatory salt iodization. Furthermore, a verification procedure involving follow-up 
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on TFT normalization and initiation of treatment was conducted for all patients 
discovered by our monitoring program within the selected time periods (figure 2).    
 
2.2.2 Study Setting 
 
An open cohort located in Northern Jutland including Aalborg City with 
surrounding municipalities, (n=309,434 by January 1
st
, 1997) was utilized for this 
study (the Western cohort from Study I&II; figure 1). Potential new cases of overt 
thyrotoxicosis and hypothyroidism discovered within the cohort area by our 
surveillance program (see section 2.1.3) during two specific periods (1997-00 vs. 
2014-16) were selected for follow-up investigation and subtype classification. The 
2014-16 period was selected because peak incidence rate of overt hypothyroidism 
was discovered by our monitoring program (Study I&II) during those years, 
meanwhile the greatest reduction in the incidence rate of thyrotoxicosis was 
observed. The study cohort comprised 272,954 subjects at the initiation of the post 
IF study period (January 1
st
, 2014), while the total amount of person-years covered 
by the post IF study period (2014-16) was 825,842. Median UIC levels within the 
cohort area were determined in 1997-98 (45 µg/l; moderate ID)
37
 and again in 2008-
10 (73 µg/l; mild ID)
39
. Detailed information on the composition of the cohort were 
provided yearly by Statistics Denmark
43
.  
 
2.2.3 Data Collection 
 
Follow-up investigation and subtype classification was performed for all new cases 
of overt thyroid dysfunction discovered within the cohort area by our diagnostic 
algorithms and subsequently verified through contact to their current GP between 
the years 1997-00 and 2014-16 (see section 2.1.3 for further details on the 
identification of potential new cases).    
The distribution of the nosological subtypes of overt thyroid dysfunction were 
described in detail for the cohort population during the years 1997-2000 before 
mandatory salt iodization
10,36
. In total 1069 potential new cases of overt thyroid 
dysfunction (thyrotoxicosis: 666, hypothyroidism: 403) were identified by our 
register database and subsequently confirmed as such by their current GPs during 
the years 2014-16. Correspondingly, during the years 1997-00 (before mandatory IF 
of salt) a total of 2011 potential new cases of overt thyroid dysfunction were 
22 
 
 
identified (thyrotoxicosis: 1601, hypothyroidism: 410). Thorough examination was 
performed of each patient’s hospital records, medicinal database (used by private 
practitioners and hospital departments), subsequent TFTs, TSH receptor antibodies 
(TRAb) measurements and thyroid scintigraphies.  
A follow-up procedure was implemented for all the 1069 cases of overt thyroid 
dysfunction identified by our surveillance program during the years 2014-16 (figure 
3). The patient would be conclusively verified (otherwise excluded) if any of the 
following were discovered to be true during the follow-up investigation:  
I) Sustained overt biochemical thyroid dysfunction, i.e. a confirmatory TFT at least 
3 weeks later.  
II) Normalization of thyroid function due to treatment for hypothyroidism (levo-
thyroxine therapy) or thyrotoxicosis (anti-thyroid medication, radioiodine therapy or 
thyroid surgery). 
III) Normalization of thyroid function without treatment but with a medical history 
suggesting a condition of transient thyroid dysfunction, such as: postpartum thyroid 
dysfunction (PPTD), subacute thyroiditis (SAT), silent thyroiditis, radioiodine-
induced thyroid dysfunction, radiation-induced thyroid dysfunction, medication-
induced thyroid dysfunction (amiodarone, lithium, interferons, interleukins and 
monoclonal antibodies) or surgical manipulation of the thyroid gland. 
 
Figure 3: Flowchart showing the process of verification for cases of overt thyroid 
dysfunction. Patients identified by the diagnostic algorithms within the cohort area, who had 
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not been registered with overt thyroid dysfunction before by either the patients’ current 
general practitioner (GP) or by the register database, constituted the pool of cases for further 
evaluation. Cases were first evaluated with respect to normalization of thyroid function tests, 
and then according to whether this normalization was the result of treatment or a case of 
spontaneous normalization. Cases of spontaneous normalization were verified as true 
hypothyroid or thyrotoxic patients if their medical history suggested a known condition of 
transient thyroid dysfunction (e.g. subacute thyroiditis, post partum thyroid dysfunction or 
one of several iatrogenic causes) otherwise they were excluded. All verified cases were 
further scrutinized to determine their nosological subtype. Copied from Study III. 
 
A total of 201 cases failed to meet any of the three above mentioned criteria and 
were thus excluded. Furthermore, 209 cases were excluded due to other specific 
exclusion criteria listed below: 
 Patients had previously suffered from overt thyroid dysfunction (n=9).  
 Patients were receiving levothyroxine or anti-thyroid medication at the time 
of diagnosis (n=115).   
 Presence of gestational transient thyrotoxicosis (n=22).  
 An elevated level of thyroid hormone binding globulin (TBG) present due 
to either pregnancy or estrogen therapy (n=11).  
 No confirmative blood test result in a patient who survived beyond 2 
months (n=6).  
 Amiodarone treatment where the thyrotoxic patients did not have an 
elevated total T3 (n=19); elevated total T4 should be expected in a patient 
with subclinical thyrotoxicosis receiving amiodarone.  
 Treatment was initiated after the patient had shifted from overt to 
subclinical thyroid dysfunction (n=14).  
 Other reasons (n=13), these included cases with pituitary disease, children 
having different reference intervals of total T4 and erroneously being 
included as cases of overt thyrotoxicosis by our algorithm, cases where 
overt thyroid dysfunction occurred several years after spontaneous 
normalization, one case where the thyroid gland was surgically removed 
before any confirmatory TFT could be performed.  
Thus, the follow-up procedure allowed for the verification of 659 patients with overt 
thyroid dysfunction out of 1069 (thyrotoxicosis: 408, hypothyroidism: 251). 
A number of patients were contacted by our research team following their diagnostic 
TFT and invited for a comprehensive investigation at our research center. This 
included: several systematic questionnaires about their medical history, 
ultrasonographic examination of the thyroid gland, thyroid scintigraphy (among 
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thyrotoxic cases), blood tests (TBG, thyroglobulin, thyrotropine receptor antibodies 
(TRAb), thyroid peroxidase antibodies (TPO-Ab), and thyroglobulin antibodies (Tg-
Ab)). Out of 1069 potential new cases discovered in 2014-16, 511 patients were 
examined at our research center (48%). During the years 1997-00, 38% of all new 
cases with overt thyroid dysfunction were examined. Full consent was obtained from 
each patient after a thorough explanation of the nature and purpose of all the 
procedures used. 
Based on their medical history, TRAb measurements and thyroid scintigraphies each 
verified case of thyroid dysfunction were classified into one of the following 
categories: 
a) Graves’ disease (GD) with thyrotoxicosis: positive TRAb measurement (TRAb+, TRAb > 
1.0 IU/l) and/or a nonsuppressed homogeneous TcO4
- uptake within the entire thyroid 
gland on scintigraphy (n=181). 
b) Multinodular toxic goitre (MNTG): a heterogeneous uptake on thyroid scintigraphy with 
at least two nodules of enhanced TcO4
- accumulation combined with absent or diminished 
uptake in the rest of the gland. If TRAb was negative or not measured, the diagnosis was 
MNTG (n=74). 
c) ‘Mixed type’ thyrotoxicosis (Marine-Lenhart syndrome): patients with a positive TRAb 
measurement but a MNTG like pattern on thyroid scintigraphy (n=71). 
d) Solitary toxic adenoma (STA): a single nodule with enhanced TcO4
- uptake combined 
with absent or low TcO4
- accumulation in rest of the thyroid gland (n=13). 
e) SAT (subacute thyroiditis/de Quervain thyroiditis): transient thyrotoxicosis and/or 
hypothyroidism, with no medical history which could otherwise explain the transient period 
of thyroid dysfunction (amiodarone, lithium, interferon, interleukin, monoclonal 
antibodies, radioiodine treatment, radiation or surgery) and with at least two of three SAT 
criteria fulfilled: anterior neck pain; absent or low TcO4
- uptake with no visible thyroid 
nodules on scintigraphy; or elevated erythrocyte sedimentation rate / C-reactive protein 
(thyrotoxicosis: n=24, hypothyroidism: n=1). 
f) Silent thyroiditis: transient thyrotoxicosis with absent or low TcO4
- uptake and no 
presence of anterior neck pain or elevated erythrocyte sedimentation rate / C-reactive 
protein. Similar to SAT, no other explanation for the transient period of thyroid 
dysfunction should be detectable in the patient’s medical history (n=6). 
g) Postpartum thyroid dysfunction (PPTD): overt thyroid dysfunction presenting within one 
year after delivery. If TRAb was negative or not measured in the case of thyrotoxicosis, 
PPTD was the diagnosis. If TRAb was positive, the patient was classified as GD 
(thyrotoxicosis: n=15, hypothyroidism: n=23). 
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h) Amiodarone-associated thyroid dysfunction: overt thyrotoxicosis or hypothyroidism 
diagnosed during or within 12 months after amiodarone treatment (thyrotoxicosis: n=6, 
hypothyroidism: n=11). 
i) Radioiodine-associated thyroid dysfunction: transient overt thyrotoxicosis developed 
within a month after radioiodine treatment of non-toxic goitre was performed, or overt 
hypothyroidism developed within one year (thyrotoxicosis: n=4, hypothyroidism: n=5). 
j) Lithium-associated thyroid dysfunction: overt thyroid dysfunction in patients previously 
(<12 months) or currently treated with lithium (thyrotoxicosis: n=5, hypothyroidism: n=4). 
k) ‘Manipulation thyroiditis’ with thyrotoxicosis: transient thyrotoxicosis developed shortly 
after thyroid manipulation during surgery on thyroid or parathyroid gland (n=3). 
l) Thyroid dysfunction associated with previous (<12months) or current treatment with 
interferon (IFN), interleukin (IL) or monoclonal antibodies (thyrotoxicosis: n=4, 
hypothyroidism: n=5). 
m) Radiation-associated thyroid dysfunction: overt thyrotoxicosis within 3 months after any 
radiation therapy against the neck region or overt hypothyroidism within one year 
(thyrotoxicosis: n=2, hypothyroidism: n=7). 
n) Surgically induced hypothyroidism: overt hypothyroidism within one year after 
hemithyrodectomi or total thyrodectomi (n=12). Patients who underwent sufficient L-T4 
substitution immediately after surgery would logically not emerge as hypothyroid. 
o) Congenital hypothyroidism: identified through the Danish neonatal screening program 
(n=3). 
p) Spontaneous hypothyroidism: overt hypothyroidism in patients without any of the above 
described conditions (n=180). We have previously shown that this combined group of 
patients with hypothyroidism due to Hashimoto’s or Ort’s disease almost exclusively 
(>99%) harbored TPO-Ab and/or Tg-Ab45. 
Textbox 1: Definitions of the different subtypes of overt thyroid dysfunction included in 
Study III and the number of cases of each subtype during the years 2014-16. The content of 
the textbox was copied directly from Study III of the present dissertation.  
 
2.2.4 Statistics 
 
Using the criteria described above, subtype classification was possible for 380 out of 
408 verified cases of overt thyrotoxicosis. A small number of patients however, 
(n=28) had no TRAb measurement or thyroid scintigraphy performed. Based on our 
examination of their medical histories, the entities e-m could be ruled out. Similar to 
the method used in our previous study, we performed nearest neighbor hot deck-
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imputation
46
 to classify this small group of patients (6.9%) into the subgroups a-d 
(GD/MNTG/mixed-type/STA: n=10/9/8/1).  Nearest neighbor hot deck-imputation 
did not have any effect on the results of the analysis. Similar to the first and second 
study the standardized incidence rates (SIRs) was calculated according to the 
principle of direct standardization
44
. However, the Danish population as of January 
1
st
, 1999 was used as the standard population to allow for comparison with data from 
the previous study during the years before initiation of effective IF (1997-2000). 
 
2.3 Study IV 
 
2.3.1 Purpose 
 
The purpose of the fourth study was to evaluate the biochemical severity (TSH and 
total T4 levels) of overt chronic autoimmune hypothyroidism at the time of diagnosis 
before and after introduction of mandatory IF in an area with pre-fortification 
moderate ID.  
 
2.3.2 Study Setting 
 
The open cohort in Northern Jutland utilized in the third study was also utilized in 
the fourth study with similar study periods: 1997-00 and 2014-16 (n=309,434 
January 1
st
, 1997; n=272,954 January 1
st
, 2014).  The median UIC levels for the 
cohort population mentioned in section 2.1.2 and 2.2.2 remain indicative for the ID 
level during these two study periods (1997-98: 45 µg/l; moderate ID
37
; 2008-10: 73 
µg/l; mild ID
39
) . Detailed information on the composition of the cohort were 
provided yearly by Statistics Denmark
43
.  
 
2.3.3 Data Collection 
 
Cases with sustained overt chronic autoimmune hypothyroidism identified within 
the cohort area using the methods described in section 2.2.3 during the two time 
periods were chosen for comparison of TSH and total T4 levels at the time of 
diagnosis. A total of 274 and 180 patients fitting these criteria were identified during 
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the years 1997-00 and 2014-16 respectively. The TSH and total T4 assays utilized 
during the two periods are described below: 
 Baseline (1997-00): Lumitest by Brahms Diagnostica (TSH reference 
interval: 0.3-4.5 mU/l), Ria Kit by Ortho-Clinical Diagnostics (total T4 
reference interval: 60-140 nmol/l) and ADVIA Centaur by Bayer (TSH 
reference interval: 0.550-4.780 mU/l, total T4 reference interval: 60-140 
nmol/l)  
 Follow-up (2014-16): Cobas 8000 modular by Roche Diagnostics (TSH 
reference interval: 0.27-4.2 mU/l, total T4 reference interval: 60-140 
nmol/l). 
Thorough examination of the differences between various TSH and total T4 assays 
can be found elsewhere
47,48
.  
 
 
2.3.4 Statistics 
 
Comparison between baseline and follow-up median values for serum TSH and total 
T4 among cases of overt chronic autoimmune hypothyroidism at the time of 
diagnosis was performed using Mann-Whitney U tests. Significance level was set at 
0.05.  
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Chapter 3: Results 
 
The following section reports the results of our monitoring program which includes 
preliminary verification of potential new cases of overt thyrotoxicosis and 
hypothyroidism through contact to the patient’s current GP (see figure 2). Thus, 
these incidence rates represent patients for whom TFT measurements indicating 
overt thyroid dysfunction were evident while no record of previous overt thyroid 
dysfunction was present with the patient’s current GP. No follow-up procedure 
investigating normalization of thyroid function and initiation of treatment was 
performed.     
 
3.1 Monitoring program for thyrotoxicosis 
 
The SIR of overt thyrotoxicosis within the two cohorts at baseline (1997-mid 98) 
before introduction of voluntary salt iodization was 128.5 and 80.1/100,000 per year 
(moderate vs. mild ID, SIRR: 1.60 (95% CI: 1.37-1.87)). Significant increases 
sharply followed by substantial decreases were observed in both cohorts (figure 4). 
Peak incidence was reached in mid 2000-01 within the moderately iodine deficient 
Western cohort (SIRR to baseline: 1.39 (1.24-1.55)) and in 2004-05 within the 
mildly iodine deficient Eastern cohort (SIRR to baseline: 1.52 (1.31-1.76)). A 
marked decline in SIR ensued within both cohorts, however due to the shorter 
follow-up period the SIR for the Eastern cohort did not reach below pre-fortification 
level at the conclusion of the study period in 2008 (SIRR to baseline: 1.12 (0.90-
1.38)). A substantial decline significantly below baseline level was however 
observed in the Western cohort which seemed to stabilize from 2010 and onward at 
around 30-40% below baseline level with final values from 2016-2017 33% below 
(SIRR: 0.67 (0.58-0.76)). The previously observed significant difference in SIR of 
thyrotoxicosis between the two cohorts at the initiation of the study was no longer 
significant by the years 2006-2007 (SIRR: 1.08 (0.96-1.23)). 
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Figure 4: Age and gender standardized incidence rates of thyrotoxicosis per 100,000 per year 
in the two cohorts from 1997 to 2017. Voluntary salt iodization: initiated in July 1998 with 8 
µg/g iodine in table salt and salt used by the food industry. Mandatory salt iodization: initiated 
in July 2000 with 13 µg/g iodine in all table salt and salt used for the production of bread. The 
error bars indicate the 95% confidence intervals (CI) for the incidence rates. Stars indicate 
statistically significant differences to baseline (1997-mid 1998; solid stars: moderate ID 
cohort, empty stars: mild ID cohort). Solid line: Western cohort in and around Aalborg City 
with moderate iodine deficiency (ID) (45 μg/L) prior to salt iodization. Dotted line: Eastern 
cohort in Copenhagen with mild iodine deficiency (61 μg/L) prior to salt iodization. The study 
period for the cohort with mild iodine deficiency was not possible beyond 2008. Copied from 
Study I 
 
The incidence rate of thyrotoxicosis was three to four times higher among women 
compared to men throughout the entire study period and within both cohort areas 
(figure 5). With data pooled from both cohorts the female preponderance in 
thyrotoxicosis incidence (female/male ratio) was 3.80 during the baseline period and 
remained around this level for the remainder of the study period. 
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Figure 5: Gender-specific incidence rates of thyrotoxicosis per 100,000 per year in the 
moderately and mildly iodine deficient cohorts from 1997 to 2017. Error bars represent 95% 
confidence intervals. Data were age standardized. Stars indicate statistically significant 
differences to baseline (solid stars: moderate ID cohort, empty stars: mild ID cohort). M = 
Males. F = Females. Grey lines = mild ID cohort. Black lines = moderate ID cohort. 
In both cohorts the incidence rate of thyrotoxicosis was strongly correlated with age during 
the baseline period. In the Western cohort with moderate ID, the age-specific incidence rates 
of thyrotoxicosis among three age groups: young (20-39 years), middle aged (40-59 years) 
and elderly (60 + years) were 49.3, 141.4 and 359.0/100,000 per year, respectively. Age-
specific incidence rates for the same three age groups within the Eastern cohort with mild ID 
were 40.8, 100.1 and 192.4/100,000 per year, respectively. Copied from Study I 
 
Significant increases in incidence rates were observed in all three age groups 
following IF within both cohorts (figure 6). Peak incidence rate of thyrotoxicosis 
within the Western cohort was observed in 2002-03 for the young and middle aged 
(SIRR to baseline, young: 2.22 (1.69-2.92); middle aged: 1.49 (1.24-1.78)) while 
peak incidence occurred immediately following mandatory IF (mid 2000-01) among 
the elderly (SIRR: 1.32 (1.14-1.52)). In the Eastern cohort peak incidence rate was 
observed in 2004-05 among all three age groups (SIRR to baseline, young: 2.50 
(1.85-3.38); middle aged: 1.43 (1.08-1.90); elderly: 1.34 (1.08-1.65)).  
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Figure 6 a-b: Age-specific incidence rates of thyrotoxicosis per 100 000 per year. Subjects 
have been split into three age groups: 20-39, 40-59 and 60 + years. Error bars represent 95% 
confidence intervals. Upper panel (a) shows data from the cohort with moderate iodine 
deficiency from 1997 to 2017. Lower panel (b) shows data from the cohort with mild iodine 
deficiency from 1997 to 2008. Copied from Study I 
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Within both cohorts the SIR of thyrotoxicosis among the younger age groups did not 
reach baseline level by the end of the study periods (SIRR to baseline, moderate ID: 
2.16 (1.59-2.95) in 2016-17; mild ID; 2.08 (1.35-3.20) in 2008). In the Eastern 
cohort with mild ID, the middle aged and elderly were at baseline level by 2008 
(SIRR to baseline, middle aged: 1.04 (0.69-1.54); elderly: 0.88 (0.65-1.20)) (figure 
6b). In the Western cohort with moderate ID, the SIR among the middle aged and 
elderly were substantially below baseline level by the end of the study period: 2016-
17 (SIRR to baseline, middle aged: 0.68 (0.53-0.87); elderly: 0.39 (0.32-0.48)). 
Differences in incidence rates were no longer detectable between the three age 
groups in the Western cohort by the end of the study period (figure 6a). Thus, a 
noticeable shift in age-specific incidence rates was seen in the cohort with previous 
moderate ID. The incidence rate of thyrotoxicosis was strongly correlated with age 
prior to IF, this was however no longer the case by the end of the study period where 
the incidence rate of overt thyrotoxicosis remained constant from the age of 30 and 
upward (figure 7).  
 
 
Figure 7: Age-specific incidence rates of thyrotoxicosis per 100 000 per year from: 1997-mid 
1998 (prior to voluntary salt iodization) and 2016-17 (long after mandatory salt iodization) in 
the Western cohort with moderate iodine deficiency prior to iodine fortification (IF). Error 
bars represent 95% confidence intervals. Copied from Study I 
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3.2 Monitoring program for hypothyroidism 
 
In the Western cohort with moderate ID, the baseline SIR of hypothyroidism was 
32.9 compared to 47.3/100,000 per year in the Eastern cohort with mild ID (SIRR: 
0.69 (95% CI: 0.54-0.90)). Following mandatory IF, the SIR of hypothyroidism 
increased significantly in both cohorts (figure 8). Peak incidence rate was observed 
in the Western cohort during the last three years of the study period (2014-16) with a 
SIRR to baseline: 1.50 (1.25-1.81). The incidence rate of hypothyroidism within the 
Eastern cohort was significantly increased from the years 2004-05 (SIRR to 
baseline: 1.30 (1.06-1.60)) and onward to 2006-07. Peak incidence rate within the 
Eastern cohort was actually observed in 2008, the difference to baseline level was 
however not statistically significant. 
 
 
Figure 8: The standardized incidence rates of hypothyroidism per 100,000 per year in the 
cohorts with mild (dotted) and moderate (solid) iodine deficiency. The rates are sex and age 
standardized to the Danish population of the year 2005. The error bars indicate the 95 % 
confidence intervals (CI) for the incidence rates. Voluntary IF:  initiated in July 1998 with 8 
µg/g iodine in table salt and salt used by the food industry. Mandatory IF:  initiated in July 
2000 with 13 µg/g iodine in all table salt and salt used for the production of bread.  
Stars indicate statistical significance to baseline (solid stars: moderate ID cohort, empty stars: 
mild ID cohort). The study period for the mildly iodine deficient cohort was concluded by the 
end of September 2008. Copied from Study II 
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The SIR of hypothyroidism among women prior to voluntary IF was 53.8 and 72.2 
/100,000 per year (moderate vs mild ID) (figure 9). The SIR among women in the 
Eastern cohort with mild ID increased significantly after introduction of mandatory 
IF with peak incidence in 2004-05 (SIRR: 1.29 (1.02-1.62)). Surprisingly, the 
increase in SIR among women in the Western cohort was not statistically significant 
until the final years (2014-16) of the study period (SIRR: 1.31 (1.06-1.63)). The SIR 
of hypothyroidism among men prior to voluntary IF was 11.4 vs. 21.8 /100,000 per 
year (moderate vs. mild ID). A significant increase in incidence rate of 
hypothyroidism after introduction of salt iodization was observed among men only 
within the Western cohort with previous moderate ID. This increase was statistically 
significant from the years 2001-02 and onward. Peak incidence was observed in 
2012-13 (SIRR: 2.54 (1.66-3.90)). No significant increase in incidence rate of 
hypothyroidism among men was seen in the Eastern cohort with mild ID. 
 
 
Figure 9: Gender specific incidence rates of hypothyroidism per 100,000 per year among 
men (M) and women (F) in the Western cohort with moderate iodine deficiency (ID) and the 
Eastern cohort with mild ID. Stars indicate statistical significance to baseline (solid stars: 
moderate ID cohort, empty stars: mild ID cohort). Incidence rates were standardized for age. 
Error bars represent 95% confidence intervals. Copied from Study II 
 
The baseline SIRs among three age groups (young: 20-39y, middle aged: 40-59y 
and elderly: 60+y) within the Western cohort with moderate ID were: 14.5, 30.8 and 
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92.2 /100,000 per year respectively (figure 10). A gradual increase in the incidence 
rate of hypothyroidism among the young was observed until 2012-13 where peak 
incidence was reached (SIRR to baseline: 2.80 (1.67-4.70)). A significant increase in 
SIR of hypothyroidism was also observed among the middle aged in the Western 
cohort, reaching peak incidence in 2014-16 (SIRR to baseline: 2.16 (1.55-3.01)). No 
significant changes in incidence rate of hypothyroidism were observed among the 
elderly throughout the study period.  
The baseline SIR of hypothyroidism among the young (20-39 y), middle-aged (40-
59 y) and elderly (60+ y) in the Eastern cohort with previous mild ID were: 16.4, 
42.2 and 148.3/100,000 per year respectively. The SIR increased significantly 
among both the young and the middle-aged following mandatory IF. Peak incidence 
rate in the young age group was observed in 2008 (SIRR to baseline: 2.62 (1.36-
5.04)). Peak incidence rate among the middle aged was reached in 2006-07 (SIRR to 
baseline: 2.19 (1.49-3.23)). Similarly to the pattern observed in the Western cohort, 
no significant changes in incidence rate of hypothyroidism were seen among the 
elderly within the Eastern cohort.  
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Figure 10 a-b:  Age specific incidence rates of hypothyroidism per 100,000 per year within 
the following age groups: 20-39, 40-59 and 60+ years for the area of moderate iodine 
deficiency (ID) (a) and mild ID (b). Stars indicate statistical significance to baseline (solid 
stars: moderate ID cohort, empty stars: mild ID cohort). Incidence rates were standardized for 
age and gender. Error bars represent 95% confidence intervals. Copied from Study II 
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3.3 Follow-up and subtype classification 
 
 
The incidence rates found in this section recounts the results obtained through our 
manual scrutiny of hospital records for all potential new cases of overt thyroid 
dysfunction discovered within the Western cohort area (previous moderate ID) 
during the years 1997-00 and 2014-16. Thus, a follow-up procedure for TFT 
normalization in relation to initiation of treatment was part of the final verification 
process and almost entirely explains any differences to the results obtained from our 
monitoring program (figure 2).  
 
 
3.3.1 Manually verified thyrotoxicosis 
 
 
Within the Western cohort with previous moderate ID the overall SIR of manually 
verified thyrotoxicosis decreased markedly from 97.5/100,000 per year in 1997-00 
(before mandatory IF was in effect) to 48.8 in 2014-16, (SIRR: 0.50 (95% CI: 0.45-
0.56)) (figure 11). Decreases in SIR were observed for MNTG from 44.5 to 8.2 
(SIRR: 0.18 (0.15-0.23)), for STA from 6.1 to 1.6 (SIRR: 0.26 (0.16-0.43)) and 
surprisingly for GD from 33.2 to 22.2 (SIRR: 0.67 (0.56-0.79)). No significant 
changes in SIR were observed for iatrogenic thyrotoxicosis (SIRR: 1.09 (0.64-
1.86)), post partum thyrotoxicosis (SIRR: 1.03 (0.53-1.99)) or mixed-type 
thyrotoxicosis (SIRR: 1.14 (0.83-1.58)). Surprisingly, the SIR of SAT increased 
significantly during the study period from 1.8 to 3.7 (SIRR: 2.07 (1.15-3.72)). The 
overall SIR of manually verified overt thyrotoxicosis among men declined from 33.0 
to 21.3 between 1997-00 and 2014-16 (SIRR: 0.65 (0.51-0.82)) while the SIR for 
women declined from 160.4 to 75.6 during the same years (SIRR: 0.47 (0.42-0.53)). 
38 
 
 
 
Figure 11: Standardized incidence rates of overt thyrotoxicosis and nosological subtypes per 
100,000 per year between 1997-00 (pre-iodine fortification period) and 2014-16 (after 
iodization of salt). Grey columns represent data from 1997-00 and white columns data from 
2014-16. Stars indicate statistical significance to baseline value (1997-00). Error bars 
represent 95% confidence intervals. Copied from Study III 
 
Decreases in SIRs of manually verified overt thyrotoxicosis were evident in all age 
groups investigated (young, middle-aged and elderly: 20-39, 40-59 and 60+ years), 
these were however only statistically significant among the middle-aged (40-59 y) 
and elderly (60+ y). From 1997-00 to 2014-16 the following changes in incidence 
rates were observed among the three age groups: young: (SIRR: 0.80 (0.63-1.02)), 
middle-aged (SIRR: 0.67 (0.56-0.80)) and elderly (SIRR: 0.30 (0.25-0.35)) (figure 
13).  
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3.3.2 Manually verified hypothyroidism 
 
The overall SIR of verified overt hypothyroidism did not change between the years 
1997-00 and 2014-16 (29.4 vs. 30.3/100,000 per year; SIRR: 1.03 (0.87-1.22)) when 
follow-up procedures were included in the verification process (figure 12). The SIR 
of chronic autoimmune hypothyroidism declined non-significantly from 23.3 to 21.6 
(SIRR: 0.93 (0.77-1.12)). The SIR of iatrogenic hypothyroidism increased non-
significantly from 3.1 to 4.8 (SIRR: 1.58 (1.00-2.50)) and post-partum 
hypothyroidism from 1.8 to 3.3 (SIRR: 1.83 (0.97-3.44)). A non-significant decline 
was observed in the SIR of hypothyroidism due to other causes (SAT and congenital 
hypothyroidism) from 1.3 to 0.6 (SIRR: 0.44 (0.17-1.16)). The SIR of overt 
hypothyroidism among men increased non-significantly from 12.6 to 16.9 (SIRR: 
1.34 (0.96-1.86)) while it decreased non-significantly among women from 45.8 to 
43.4 (SIRR: 0.95 (0.78-1.15)). 
 
Figure 12: Standardized incidence rates of overt hypothyroidism and nosological subtypes 
per 100,000 per year between 1997-00 (pre-iodine fortification period) and 2014-16 (after 
iodization of salt). Grey columns represent data from 1997-00 and white columns data from 
2014-16. Error bars represent 95% confidence intervals. Copied from Study III 
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The impact of mandatory IF on the SIR of overt verified hypothyroidism among the 
three aforementioned age groups was surprisingly different (figure 13). Among the 
young (20-39 y) a significant increase in SIR was present from 14.7 to 26.5 (SIRR: 
1.81 (1.20-2.72)), while a non-significant increase was evident among the middle-
aged from 33.0 to 43.8 (SIRR: 1.33 (1.00-1.77)). A significant decrease in SIR was 
however present among the elderly (60+ y) from 76.5 to 48.1 (SIRR: 0.63 (0.49-
0.80)). These opposing changes in SIR of overt verified hypothyroidism observed 
between the three age groups after introduction of mandatory IF prevented an 
increase in the overall SIR of hypothyroidism for the whole population.   
 
 
Figure 13: Relative change in standardized incidence rate of overt thyrotoxicosis and 
hypothyroidism between 1997-00 and 2014-16 among three age groups (20-39, 40-59 and 
60+ years). Black arrows represent overt thyrotoxicosis and grey arrows represent overt 
hypothyroidism. Stars indicate significant change from baseline value (1997-00). Copied from 
Study III 
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3.4 Thyroid function test results in hypothyroidism 
 
Median serum TSH among manually verified patients with overt chronic 
autoimmune hypothyroidism at the time of diagnosis was 40.4 mU/l in 1997-00 
(before IF) and 20.5 mU/l after IF in 2014-16 (P<0.001) (table 1). Median TSH 
among men were 49.1 mU/l before IF vs. 16.2 mU/l after IF (P<0.001) while 
corresponding values among women were 37.8 mU/l before IF vs. 24.7 mU/l after 
IF (P<0.01). The TSH medians among different age groups (20-39, 40-59, 60-79, 
80+ years) were lower after introduction of mandatory IF (2014-16) compared to 
before (1997-00), though only significant for the age groups 40-59, 60-79 and 80+ 
years (P-values<0.05) (figure 14). This was likely due to insufficient statistical 
power within the youngest age group (20-39 years). 
 
Table 1: Serum thyroid stimulating hormone (TSH mU/l) and total thyroxine (TT4 nmol/l) 
values among patients with overt chronic autoimmune hypothyroidism (Hashimoto’s 
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thyroiditis: HT) from 1997-00 (before IF) and 2014-16 (after IF). Mann-Whitney U test for 
median difference between 1997-00 and 2014-16: P < 0.001 (TSH and TT4 both). Copied 
from Study IV 
 
Among patients with overt chronic autoimmune hypothyroidism the median serum 
total T4 at the time of diagnosis was 41 nmol/l in 1997-00 (before IF), and 52 nmol/l 
in 2014-16 (after IF) (P<0.001) (table 1). Median total T4 among men was 34 nmol/l 
before mandatory IF and 52 after (P= 0.021). Corresponding values among women 
were 42 nmol/l before IF and 52 after IF (P< 0.001). Among all the age groups (20-
39, 40-59, 60-79, 80+ years) the total T4 medians were higher in 2014-16 than in 
1997-00, though only statistically significant for the 40-59, 60-79 and 80+ year age 
groups (figure 15). Exclusion of women with high estrogen levels (birth control or 
hormone replacement) from the analysis did not change any of the results. 
  
  
Figure 14: Median serum thyroid stimulating hormone (TSH mU/l) among patients with 
overt chronic autoimmune hypothyroidism at the time of diagnosis within specific age groups 
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before (1997-00) and after (2014-16) introduction of mandatory salt iodization in Denmark. 
Varying degrees of statistical significance to the baseline values (1997-00) are indicated as 
follows: * P-value < 0.05. ** P-value < 0.01. *** P-value < 0.001. Copied from Study IV 
 
 
Figure 15: Median serum total T4 among patients with overt chronic autoimmune 
hypothyroidism at the time of diagnosis within specific age groups before (1997-00) and after 
(2014-16) introduction of mandatory salt iodization in Denmark. Varying degrees of 
statistical significance to the baseline values (1997-00) are indicated as follows: * P-value < 
0.05. ** P-value < 0.01. *** P-value < 0.001. Copied from Study IV 
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3.5 TSH testing rate within the Western cohort 
 
The TSH testing rates (diagnostic and therapeutic testing combined) within the 
Western cohort area increased substantially during the study period for both genders 
and all age groups above 20 years (table 2). For men and women respectively, the 
total TSH testing rate (diagnostic and therapeutic testing combined) increased from 
1,560 and 4,018 per 10,000 per year at baseline (1997-00) to 4,839 (+210%) and 
7,837 (+95%) during follow-up (2014-16).  
 
Table 2: Thyroid stimulating hormone (TSH) test rate (per 10,000 per year) among men and 
women at different ages before mandatory salt iodization (1997-00) and after (2014-16). 
Relative increase (%) in TSH test rate from 1997-00 to 2014-16 are shown. An asterix 
indicates the exclusion of individuals below the age of 20 years, thus the TSH testing rate in 
the bottom row marked “Total age” only includes adult individuals (20+ years). Copied from 
Study IV 
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Chapter 4: General discussion 
 
4.1 Main findings 
 
In the area with previous moderate ID, a substantial reduction in the incidence rate 
of overt thyrotoxicosis was observed after the initiation of mandatory IF. Our 
partially automated monitoring program estimated this reduction to be around 33% 
between 1997-98 and 2016-17. Correspondingly, our manual follow-up procedure 
for cases identified by our monitoring program during the years 1997-00 and 2014-
16 revealed a 50% reduction in the incidence rate of overt thyrotoxicosis, when 
cases with spontaneous normalization of thyroid function and no medical history 
suggesting a condition with transitory thyroid dysfunction were excluded from the 
analysis. This decline in incidence rate of overt thyrotoxicosis was the result of 
marked decreases in the MNTG, STA and GD incidences. Unsurprisingly, both our 
monitoring program and our manual follow-up study revealed major effects among 
the elderly and minor effects among the young.  
Marked increases in the incidence rate of overt hypothyroidism were discovered by 
our monitoring program in both cohort areas. These effects were most pronounced 
among the young and entirely absent among the elderly. Interestingly, our manual 
follow-up procedure for cases discovered by our monitoring program revealed that 
the overall incidence rate of overt hypothyroidism had remained unchanged between 
1997-00 and 2014-16, when cases with spontaneous normalization of thyroid 
function and no medical history suggesting a condition with transitory thyroid 
dysfunction were excluded from the analysis. Significant differences were however 
present between the different age groups investigated. A marked increase in 
incidence rate of overt hypothyroidism was found among the young while a marked 
decrease was discovered among the elderly, resulting in an unaltered overall 
incidence rate for the entire population.  
A 126% increase in the TSH testing rate was discovered in the Western cohort area 
between 1997-00 and 2014-16. This is the most likely explanation for the markedly 
lower median TSH value and markedly higher total T4 value observed among 
patients with chronic autoimmune hypothyroidism at the time of diagnosis after 
introduction of mandatory salt iodization.   
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4.2 Comparison with other studies 
 
4.2.1 Thyrotoxicosis 
 
The reductions in thyrotoxicosis incidence observed in the studies of the present 
dissertation are in accordance with observations from several other countries. In 
1980, salt iodization was increased from 7.5 to 15 µg/g in Switzerland
49
. This was 
accompanied by a 56% decrease in the overall incidence rate of thyrotoxicosis
49
. 
MNTG and GD incidence rates declined 73% and 33% respectively, while 82% and 
33% decreases was observed in Study III of the present dissertation. These result are 
however not entirely comparable as the population of Switzerland changed from 
mild ID to adequate iodine intake during the course of the study while our cohort 
area increased from moderate to mild ID as a result of mandatory salt iodization. 
Furthermore, the results from the Swiss study are based exclusively on referral of 
patients to a single hospital, whereas our data were obtained from GPs, hospital 
departments and specialists with private practices, thus leaving no possibility of 
cases with overt thyroid dysfunction evading our algorithm.  
Salt iodization in Austria was increased from 7.5 to 15 µg/g in 1990 and all cases of 
thyrotoxicosis referred to 14 departments of nuclear medicine were recorded from 
1987-1995
17
. The observed pattern of initial increase and subsequent decline in 
thyrotoxicosis incidence in the Austrian study does somewhat resemble the pattern 
observed through our monitoring program. However, no clear comparison can be 
made due to the many methodological discrepancies and the very short follow-up 
period after increased salt iodization in the Austrian study.  
A major rise in thyrotoxicosis incidence was observed in Tasmania after iodization 
of bread salt and introduction of iodophores in the dairy industry in the year 
1966
14,50
. The incidence rate increased markedly from 24 / 100,000 / year before IF 
to reach peak incidence rate in 1967 at 125 / 100,000 / year. Similar to most other 
studies the results from Tasmania were based on hospital referrals and thus direct 
comparison to our monitoring program remains difficult. A more than fivefold 
increase in incidence rate of thyrotoxicosis does appear extraordinary compared to 
the 39% and 52% increases discovered in our cohort areas. The explanation for a 
difference of this magnitude remains elusive.  
In 1999 salt iodization in Slovenia was increased from 10 to 25 µg/g. Referrals of 
GD, MNTG and STA patients to the University Medical Centre Ljubljana were 
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monitored from 1999 to 2009
51
. By 2009 the MNTG and STA incidence had 
decreased by 27% while no change in GD incidence occurred.                        
The prevalence of MNTG, STA and GD was investigated in a rural community in 
Northern Italy before and after introduction of voluntary salt iodization at a level of 
30 µg/g in 2005
22
. There was no significant difference in prevalence of MNTG, STA 
or GD between 1995 and 2010.  
The first and second cross-sectional studies within DanThyr (see section 1.1.3) 
found decreased prevalence of subclinical thyrotoxicosis between 1997-98 and 
2004-05 but no significant decrease in the prevalence of overt thyrotoxicosis. This 
seems in accordance with the findings of our cohort studies where a significantly 
decreased incidence rate of overt thyrotoxicosis did not occur before the years 2006-
07. A lower frequency of solitary and multiple thyroid nodules were discovered 
between the first cross sectional study in 1997-98 and the follow-up study performed 
in 2008-10, when comparing participants of similar age at the time of 
ultrasonographic examination
52
. A lower frequency of thyroid nodules among 
participants of the same age ought to be expected given the substantial reductions in 
MNTG and STA incidence rates observed in our study.    
The marked decline in MNTG and STA incidence observed in Study III of this 
dissertation, should account for the substantial reduction in the use of radioiodine 
treatment observed on a national scale in Denmark between 1997 and 2015 (47.7 vs. 
33.1 / 100,000 / year)
21
. Furthermore, the use of anti-thyroid medication declined 
23% on a national scale between 1997 and 2014
21
. The incidence rates of MNTG 
and STA should not be expected to have decreased equally in all areas of Denmark 
as significant differences in the occurrence of these conditions existed between areas 
with mild and moderate ID prior to the introduction of mandatory salt iodization
10
. 
Thus, the results from the national registries (mild and moderate ID prior to IF) are 
not incompatible with the results of our studies in which only the cohort with 
previous moderate ID could be investigated during the years 2014-16.   
 
4.2.2 Hypothyroidism 
 
The results from our monitoring program of hypothyroidism incidence within the 
moderately iodine deficient cohort area (Study II) could superficially seem 
contradictory to those of our follow-up study (Study III), as the former found a 50% 
increase in the incidence rate of overt hypothyroidism during the years 2014-16 
while the latter found this increase to be completely absent during the same years. 
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These results are however not at all contradictory when scrutinizing the details. 
There was indeed a 50% increase in the number of new patients with overt 
hypothyroidism (TSH>5.0 mU/l and total T4<60 nmol/l) in the cohort area. 
However, when cases with spontaneous normalization of thyroid function (i.e. 
without treatment) and no medical history suggesting a typical condition causing 
transitory thyroid dysfunction were excluded, this 50% increase vanished entirely. 
Thus, the criteria used for categorizing hypothyroidism in a study population appear 
to be of paramount importance for the comparability of the results to those of other 
studies, as the conclusion drawn from a study can be entirely different depending on 
the criteria used to define hypothyroidism (transitory hypothyroidism with 
spontaneous normalization vs. sustained hypothyroidism requiring treatment). 
Evaluating the impact of various IF programs on the incidence rate of 
hypothyroidism is further complicated by several other possible differences in study 
design. Such differences may involve: inclusion of both subclinical and overt 
hypothyroidism, including only referred cases of hypothyroidism, including specific 
thyroid auto-antibodies levels and ultrasonographic patterns in the definition of 
hypothyroidism, differences in the level of ID prior to IF and the magnitude of IF. 
In Italy, the prevalence of Hashimoto’s thyroiditis (HT) increased significantly after 
introduction of voluntary salt iodization in 2005
22
. The prevalence of HT rose from 
2.8% in 1995 to 5.0% in 2010, though this increase was entirely driven by a greater 
number of cases among children (<15 years). An increased prevalence of thyroid 
autoantibodies was also reported between 1995 and 2010 (12.6% vs. 19.5%). 
Straight comparison to our results is complicated by the criteria used to define HT in 
the Italian study. A mixture of TFTs, ultrasonographic pattern (hypoechoic) and 
concentrations of thyroid auto-antibodies were utilized for the identification of HT 
cases. These compound criteria allowed for the inclusion of subclinically 
hypothyroid or even euthyroid cases in certain circumstances.  
From 1999 to 2009 the incidence rate of Hashimoto’s thyroiditis increased 127% in 
Slovenia presumably as a result of salt iodization having been initiated in 1999
51
. 
These results are however not comparable to ours as both subclinical and overt 
hypothyroidism was included in the analysis and the incidence rates were based 
solely on referral to a single hospital department.  
The prevalence of overt and subclinical hypothyroidism was investigated in three 
areas of Hungary and Slovakia with different median UICs (72, 100 and 513µg/g 
creatinine)
53
. The prevalence of overt hypothyroidism in these areas was 0.8%, 
1.5%, and 7.6% respectively, while the prevalence of subclinical hypothyroidism 
was 4.2%, 10.4%, and 23.9% respectively. These results are in fact somewhat 
comparable to our results as we found significant increases in incidence rate of 
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hypothyroidism among the younger age groups but not among the elderly. Even if 
the overall incidence rate of hypothyroidism for the entire population remains 
constant, a shift in the age distribution towards the young would cause the 
prevalence of overt hypothyroidism to increase over time, as the elderly patients 
presumably cannot be expected to survive with the condition for as long as young 
patients.   
In Denmark the incident use of thyroid hormone therapy nearly doubled from 1997-
2014
21
. Given that the incidence of overt treatment-requiring hypothyroidism did not 
increase from 1997-00 to 2014-16 (Study III), the explanation for this vast increase 
in thyroid hormone therapy use is likely to be found in increased treatment of 
subclinical hypothyroidism (see section 5 for further elaboration on this point). 
 
 
4.3 Possible mechanisms involved 
 
4.3.1 Thyrotoxicosis 
 
The current conception of how autonomous thyroid nodules develop as a result of 
iodine deficiency is summarized below
54
: 
Iodine deficiency and reduced substrate availability for thyroid hormone production 
could cause increased TSH secretion from the pituitary gland. TSH then induces 
hyperplasia and increased functional activity among the thyrocytes. This may in turn 
lead to increased mutagenesis through the formation large quantities of H2O2 and 
other reactive oxygen species (ROS). Gain of function mutations could then occur in 
genes regulating thyrocyte growth and thus lead to the emergence of autonomous 
thyrocyte clones
54
. 
Correction of iodine deficiency should hence reduce the development of 
autonomously functioning nodules among a previously iodine deficient population. 
This seemingly accounts for the substantial reduction in MNTG and STA incidence 
rates observed in our study. The reduction in the frequency of non-toxic multiple 
and solitary thyroid nodules observed in the C1b follow-up study (DanThyr) among 
subjects of similar age at the time of examination are likely to be caused by the same 
mechanism.   
50 
 
 
The reduced incidence rate of GD observed in Study III may be explained by two 
factors: 
1) The incidence rate of overt thyrotoxicosis did in fact increase significantly 
when voluntary salt iodization was introduced and peaked around the 
period mid 2000-01. This increase was most pronounced among the 
younger age group and likely the product of increased GD occurrence as 
MNTG is extremely rare in this age group. Correspondingly, only a 
relatively small increase in thyrotoxicosis incidence was discovered among 
the elderly for whom MNTG was the leading cause of overt thyrotoxicosis. 
Thus, this initial increase in thyrotoxicosis incidence was likely to be 
caused by GD and not MNTG. If the otherwise insufficient voluntary salt 
iodization managed to cause a transitory increase in GD incidence this 
would result in an overestimation of GD incidence prior to mandatory IF. 
This seems unlikely to be relevant for MNTG due to the aforementioned 
skewed age distribution of the increased incidence rate of thyrotoxicosis, 
and not likely to be important for hypothyroidism at all since the voluntary 
salt iodization did not result in any increased incidence rate.    
2) Smoking is positively associated with the severity and onset of GD55. 
Hence the decreased frequency of smoking among the Danish population 
might be of some importance in explaining the decreased incidence rate of 
GD observed in Study III of this dissertation.  
 
4.3.2 Hypothyroidism 
 
Alterations in the level of thyroid autoimmunity and accompanying thyroid failiure 
could be a tempting explanation for the impact of IF on the incidence rate of 
hypothyroidism. In the DanThyr cross-sectional studies, the prevalence of thyroid 
peroxidase antibody (TPO-Ab) positivity increased significantly from 14.3% in 
1997-98 to 23.8% in 2004-05
23
. Furthermore, a clear association between elevated 
TSH and TPO-Ab level has been established
23,24
. The largest increase in prevalence 
of TPO-Ab positivity was found among the young while only small increases were 
found among the elderly
23
. This is in accordance with the findings of our current 
studies in which increased incidence rate of hypothyroidism was discovered among 
the young but not among the elderly. 
Several other studies have also suggested autoimmunity as the likely explanation for 
the rise in occurrence of hypothyroidism following salt iodization
9,56–58
. Some 
evidence suggests that auto-regulatory processes within the thyroid gland involving 
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arachidonic acid derivates might be of importance in inducing hypothyroidism 
following IF as a way to protect against iodine overload
59
. 
During the course of the last two decades a marked reduction in the frequency of 
smoking has occurred in Denmark
60
. This is likely of importance to our results as a 
negative association between smoking and TPO-Ab positivity was observed in the 
DanThyr cross-sectional studies
61
. Thus, the decreased frequency of smoking should 
be accompanied by an increased prevalence of TPO-Ab positivity.   
The lower median serum TSH and higher median serum total T4 observed among 
patients with chronic autoimmune hypothyroidism at the time of diagnosis during 
the years 2014-16 is quite likely to be the direct result of the vastly increased rate of 
TSH testing discovered in the cohort area between 1997-00 and 2014-16. As chronic 
autoimmune thyroiditis causes a gradual decline in the capacity for thyroid hormone 
production, TSH should be expected to slowly increase while total T4 subsequently 
decreases among affected individuals. An increased TSH testing rate should allow 
for earlier detection of these TSH and total T4 derangements, thus resulting in lower 
median TSH and higher median total T4 values at the time of diagnosis.  
TSH testing rates differ considerably between various countries. Studies from Great 
Britain
62
, Scotland
62
 and New Zealand
63
 revealed TSH testing rates of around one in 
six adults per year. The TSH testing rate among adults in Australia in 2016-17 was 
2,874 per 10,000 per year
64
. This highly resembles the TSH testing rate in our 
Western cohort before mandatory salt iodization was in effect (1997-00). The TSH 
testing rate among adults increased to a remarkable 6,335 per 10,000 per year in the 
Western cohort during the years 2014-16 (Study IV). 
Discovering hypothyroidism at an earlier stage could have important beneficial 
effects as overt hypothyroidism is associated with increased mortality rates
65
 and 
specifically the duration of overt hypothyroidism is correlated with all-cause 
mortality
66
. Early diagnosis and subsequent treatment of these patients should reduce 
their mortality rate as well as their risk of psychiatric disease and their likelihood of 
receiving disability pension
67,68
. Importantly, subclinical hypothyroidism does not 
seem to be associated with increased mortality rates
66
.  
 
4.4 Implications for IF programs 
 
Even a very cautious salt iodization program (<50 µg increase in average daily 
intake) managed to successfully reduce the incidence rate of nodular toxic goitre 
(MNTG: ÷82% and STA: ÷74%) among a population with previous moderate ID, 
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thus causing an overall decline in incidence rate of overt thyrotoxicosis of around 
50% in only 14-16 years. A less pronounced effect on thyrotoxicosis incidence 
ought to be expected in areas with less severe ID as the disease burden of nodular 
toxic goitre should be significantly lighter in such areas. A transient increase in the 
incidence rate of overt thyrotoxicosis during the initial period following salt 
iodization seem unavoidable and appears to be particularly impactful among the 
younger age groups.  
A significant increase in the incidence rate of overt hypothyroidism among 
individuals <40 years should be expected when introducing mandatory salt 
iodization of this magnitude, though this may to some extent be compensated by 
fewer cases among the elderly in areas of moderate ID. This increased incidence rate 
of overt hypothyroidism among the young might be rendered less impactful by an 
increased TSH testing rate as diagnosis can be made earlier and at less severe stages 
of TFT derangement.  
Increasing the Danish salt iodization further should be engaged with caution. 
Increasing the median UIC of the population to the 150 µg/l recommended by WHO 
might be undesirable among the Danes, as a further reduction in the burden of 
nodular toxic goitre seems unobtainable and an increased incidence rate of overt 
hypothyroidism seems unavoidable among the young. A median UIC just above 100 
µg/l could represent the level of iodine intake with the lowest frequency of overt 
thyroid dysfunction among the Danish population.    
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Chapter 5: Methodological considerations 
 
It appears quite likely that treatment of subclinical thyroid dysfunction and 
subclinical hypothyroidism in particular has become more frequent during the 
course of our study period
69
. This would be a limitation of considerable importance 
as initiation of treatment among subclinically hypothyroid patients would prevent 
them from becoming overtly hypothyroid. This would naturally lead to an 
underestimation of the increase in incidence rate of hypothyroidism caused by 
introduction of salt iodization as properly treated hypothyroid patients would be 
prevented from proceeding to overt hypothyroidism. Chronic autoimmune 
hypothyroidism should be of particular interest with regards to the effects of 
initiating treatment of subclinical thyroid dysfunction as the condition encompasses 
a slow gradual decline in thyroid hormone production and thus ample time for 
intervention and initiation of treatment prior to transitioning to overt 
hypothyroidism. The increased TSH testing rate discovered in Study IV would lead 
to the discovery of more subclinically hypothyroid patients in our cohort area. If this 
effect was to be combined with a lower s-TSH threshold for initiation of treatment 
among hypothyroid individuals we should expect that a larger quantity of patients, 
who would otherwise become overtly hypothyroid during our study period, could be 
prevented from transitioning to overt hypothyroidism. Some evidence suggest that 
the s-TSH threshold for initiating L-T4 treatment among hypothyroid patients has 
decreased in the Danish capital Copenhagen between 2001 and 2015
69
. Among 
hypothyroid patients the median s-TSH at which L-thyroxine treatment was initiated 
decreased from 10 mU/l in 2001 to 6.8 mU/l in 2015. Meanwhile, the annual s-TSH 
testing rate increased 164% between 2001 and 2015
69
.   
The increased s-TSH testing rate discovered in our Western cohort between 1997-00 
and 2014-16 should lead to an inflated incidence rate of overt thyroid dysfunction in 
the later parts of our study period. An increased s-TSH testing rate ought to diminish 
the pool of undiagnosed patients with overt thyroid dysfunction. Indeed, the 
prevalence of undiagnosed overt thyrotoxicosis decreased 61% between 1997-98 
and 2004-05 while a 91.2% decrease in the prevalence of undiagnosed overt 
hypothyroidism was discovered during the same period
70
. Though we are unable to 
separate diagnostic from therapeutic TFT sampling, we would consider it quite 
unlikely that the more than doubling in s-TSH testing rate was the sole product of 
increased s-TSH sampling among patients with known overt thyroid dysfunction. In 
an urban population in Exeter in the year 2012, only 17% of s-TSH tests were 
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sampled from subjects who were currently or previously under treatment for thyroid 
dysfunction
71
. Similarly, in the San Antonio Military Health System 30% of TSH 
measurements were sampled from patients with a known history of 
hypothyroidism
72
.    
The incidence rates reported in the studies of this dissertation should correctly be 
termed “diagnostic incidence rates” as true incidence rates require continues testing 
of one group of individuals over the course of several years to determine the exact 
number of subjects who develop the condition in question. Monitoring all the 
subjects within our cohort areas with yearly TFTs would require insurmountable 
resources and monitoring a much smaller area in the same fashion would render a 
number of events too small for any meaningful analysis given the relatively low 
frequency of overt thyroid dysfunction. Thus, we had to accept utilizing the cases of 
overt thyroid dysfunction discovered through the diagnostic activity of private 
practices and hospital departments in our cohort areas. 
The iodine intake of our cohort populations may not have been entirely stable after 
the introduction of mandatory salt iodization. Though the median UIC within the 
Western cohort had increased from 45 µg/l in 1997-98 to 86 µg/l in 2004-05, a slight 
decline in median UIC was observed during the follow-up study in 2008-10 (73 
µg/l)
73
. This decline in median UIC could be the result of reduced iodine content in 
diary products
73
. Newer studies regarding the iodine intake in the Western cohort are 
required to investigate this. 
The impossibility of continuing our surveillance of the Eastern cohort with previous 
mild ID is unfortunate and allows for a greater degree of ascertainment bias in our 
evaluation of the impact of mandatory salt iodization on overt thyroid dysfunction. 
A technical difficulty combined with staff limitations made continues verification of 
incident cases impossible beyond the year 2008 in the Eastern cohort. Thus, the 
effect of mandatory salt iodization on the incidence rates of over thyroid dysfunction 
under conditions of mild ID remains to be elucidated.   
As all TFTs sampled among GPs, hospital departments and specialists with private 
practice within our cohort areas were included, our method substantially reduces the 
impact of the referral biases
74
 typically associated with studying incidence rates of 
thyroid dysfunction in relation to IF programs
14,17,49–51
. 
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Chapter 6: Conclusions 
 
Mandatory salt iodization in Denmark caused a less than 50 µg increase in average 
daily iodine intake yet striking reductions in the incidence rate of nodular toxic 
goitre ensued (MNTG: ÷82% and STA: ÷74%) leading to a 50% decline in the 
overall incidence rate of overt thyrotoxicosis. Even if the incidence rate of overt 
hypothyroidism did not increase among the population as a whole, the incidence rate 
among the young (<40 years) did increase markedly (+81%). This age group should 
be granted special attention when initiating IF programs in the future. The s-TSH 
testing rate among the Danish population has more than doubled in less than 20 
years which is the likely explanation for the observed reduction in median s-TSH 
among overtly hypothyroid patients at the time of diagnosis. Monitoring thyroid 
dysfunction in an area using simple TFT algorithms and subsequent verification 
with GPs can be almost fully automated and should provide a reasonable estimate 
for the impact of IF among an iodine deficient population. Manual scrutiny of the 
medical records of all possible new cases of thyroid dysfunction within an area is a 
labor and time consuming process, though important knowledge about the severity, 
duration, need for treatment and nosological subtype of thyroid dysfunction is only 
obtainable this way.  
Increasing the level of salt iodization in Denmark would be unlikely to succeed in 
reducing the burden of nodular toxic goitre further in any significant degree. 
Whereas an increased incidence rate of overt hypothyroidism among young subjects 
(<40 years) seems likely. Thus, aiming for a median UIC of 150 µg/l as 
recommended by WHO could be undesirable among the Danish population. A 
median UIC just above 100 µg/l would still be within the normal range and may 
ensure less of a thyroid dysfunction related disease burden among the young.        
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Chapter 7: Perspectives and future research 
 
The impact of salt iodization on the incidence rate of subclinical thyroid dysfunction 
remains to be elucidated and seems to be a topic of increasing concern. Our current 
Register Database unfortunately cannot provide accurate information on the number 
of new cases of subclinical of thyroid dysfunction before and after the initiation of 
salt iodization in Denmark. The DanThyr cross-sectional studies report the 
prevalence of subclinical thyroid dysfunction before and after IF yet we have no 
indication of the prevalence of these conditions past the year 2010. A new cross-
sectional study could provide crucial information on this increasingly important 
topic.  
The effects of salt iodization on the incidence rates of overt thyroid dysfunction 
among subjects with previous mild ID remain to be investigated past the year 2008. 
This should be of considerable interest given how widespread mild ID was among 
the Danish population prior to initiation of IF and because the effects of IF on 
thyroid dysfunction in mild ID areas likely differ considerably from those seen in 
areas with moderate ID. 
Around one third to one half of all subjects presenting with overt thyroid 
dysfunction within the cohort area with previous moderate ID were interviewed and 
examined at our research centre in Aalborg. Thyroid auto-antibodies (TRAb, TPO-
Ab and Tg-Ab) and other thyroid related blood tests (TBG and thyroglobulin) were 
measured among all subjects and the data from these examinations remain to be 
analyzed. Furthermore, data on: smoking status, diet, medicine, pregnancies and 
ultrasonographic examination of the thyroid are available for all of the subjects 
interviewed in our Research Centre. These data may provide answers to many 
questions of interest with regard to the impact of mandatory IF on thyroid function. 
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